Fortress Biotech (FBIO) Competitors $1.72 -0.02 (-1.15%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FBIO vs. LXRX, ACHV, RGLS, AGEN, SABS, CRIS, BOLT, MTEM, AMGN, and VRTXShould you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Agenus (AGEN), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "biotechnology" industry. Fortress Biotech vs. Lexicon Pharmaceuticals Achieve Life Sciences Regulus Therapeutics Agenus SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Lexicon Pharmaceuticals (NASDAQ:LXRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Which has stronger valuation & earnings, LXRX or FBIO? Fortress Biotech has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$5.23M33.66-$177.12M-$0.75-0.95Fortress Biotech$62.50M0.76-$60.64M-$3.05-0.56 Does the media favor LXRX or FBIO? In the previous week, Lexicon Pharmaceuticals had 7 more articles in the media than Fortress Biotech. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.38 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Overall Sentiment Lexicon Pharmaceuticals Neutral Fortress Biotech Neutral Does the MarketBeat Community believe in LXRX or FBIO? Lexicon Pharmaceuticals received 153 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 64.78% of users gave Lexicon Pharmaceuticals an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48064.78% Underperform Votes26135.22% Fortress BiotechOutperform Votes32763.62% Underperform Votes18736.38% Is LXRX or FBIO more profitable? Fortress Biotech has a net margin of -84.53% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Fortress Biotech's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Fortress Biotech -84.53%N/A -34.93% Which has more risk and volatility, LXRX or FBIO? Lexicon Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Do analysts rate LXRX or FBIO? Lexicon Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 739.51%. Fortress Biotech has a consensus price target of $13.67, suggesting a potential upside of 694.57%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Fortress Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in LXRX or FBIO? 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryFortress Biotech beats Lexicon Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBIO vs. The Competition Export to ExcelMetricFortress BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.48M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.5610.4289.5817.17Price / Sales0.76195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book17.205.094.774.78Net Income-$60.64M$151.83M$120.15M$225.60M7 Day Performance-11.34%-2.13%-1.92%-1.23%1 Month Performance9.21%-3.10%11.47%3.36%1 Year Performance-32.02%11.54%30.54%16.60% Fortress Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBIOFortress Biotech3.1488 of 5 stars$1.72-1.1%$13.67+694.6%-27.1%$47.48M$62.50M-0.56186LXRXLexicon Pharmaceuticals1.8091 of 5 stars$0.82+1.0%$6.00+633.4%-41.4%$201.45M$5.23M-1.08285News CoverageACHVAchieve Life Sciences2.009 of 5 stars$4.11+0.2%$14.80+260.1%+8.8%$141.34MN/A-3.6320RGLSRegulus Therapeutics2.7405 of 5 stars$1.67+5.4%$10.80+548.6%+20.5%$109.06MN/A-1.4830News CoveragePositive NewsAGENAgenus3.6862 of 5 stars$2.87-5.9%$10.00+248.4%-81.2%$67.33M$160.43M-0.27389SABSSAB Biotherapeutics2.4276 of 5 stars$3.99-2.2%$12.40+210.8%+520.0%$36.82M$2.24M0.00140Gap UpCRISCuris2.7846 of 5 stars$3.71+3.9%$23.00+519.9%-74.6%$31.41M$10.26M-0.4849BOLTBolt Biotherapeutics2.4727 of 5 stars$0.51-2.6%$3.50+580.9%-50.5%$19.67M$7.88M-0.31100MTEMMolecular Templates3.1832 of 5 stars$0.39-3.1%N/A-95.7%$2.55M$57.31M-0.1562News CoverageGap DownAMGNAmgen4.4715 of 5 stars$269.39-0.5%$319.68+18.7%-4.3%$144.81B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7526 of 5 stars$466.88+0.7%$505.73+8.3%-0.7%$120.24B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies LXRX Alternatives ACHV Alternatives RGLS Alternatives AGEN Alternatives SABS Alternatives CRIS Alternatives BOLT Alternatives MTEM Alternatives AMGN Alternatives VRTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FBIO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FBIO Stock Alerts